---
figid: PMC9311918__antioxidants-11-01304-g001
pmcid: PMC9311918
image_filename: antioxidants-11-01304-g001.jpg
figure_link: /pmc/articles/PMC9311918/figure/antioxidants-11-01304-f001/
number: Figure 1
figure_title: ''
caption: 'The common mTOR signalling pathway in ocular neurodegenerative diseases.
  Abbreviations: AMP’, 5’ adenosine monophosphate-activated protein kinase; ATF4,
  activating transcription factor 4; ATG, autophagy-regulating protease; BNIP3L, adenovirus
  E1B 19 kDa protein-interacting protein 3-like; CHOP, C/EBP homologous protein; ER,
  endoplasmic reticulum; HIF-1α, hypoxia-inducible factor 1-alpha; HO-1, heme oxygenase-1;
  mTORC1, mammalian target of rapamycin complex 1; Nrf2, nuclear factor-erythroid
  factor 2-related factor 2; PERK, protein kinase R (PKR)-like endoplasmic reticulum
  kinase; PI3K, phosphoinositide 3-kinase; PINK1, PTEN-induced kinase 1; REDD1, regulated
  in development and DNA damage responses 1; Rheb, ras homolog enriched in brain;
  ROS, reactive oxygen species; TFEB, transcription factor EB; TSC, tuberous sclerosis
  complex; ULK1, unc-51-like kinase 1; VPS34, vacuolar protein sorting 34.'
article_title: 'mTOR Signalling Pathway: A Potential Therapeutic Target for Ocular
  Neurodegenerative Diseases.'
citation: Yipin Wang, et al. Antioxidants (Basel). 2022 Jul;11(7):1304.
year: '2022'

doi: 10.3390/antiox11071304
journal_title: Antioxidants
journal_nlm_ta: Antioxidants (Basel)
publisher_name: MDPI

keywords:
- mTOR
- AMD
- DR
- glaucoma
- oxidative stress
- hypoxia
- inflammation
- ROS
- rapamycin
- clinical trial

---
